Vacina de ARNm (Galician Wikipedia)

Analysis of information sources in references of the Wikipedia article "Vacina de ARNm" in Galician language version.

refsWebsite

Global rank Galician rank

58doi.org

2^nd place

7^th place

57nih.gov

4^th place

6^th place

46web.archive.org

1^st place

8worldcat.org

5^th place

11^th place

8harvard.edu

18^th place

38^th place

4fda.gov

447^th place

749^th place

3cdc.gov

218^th place

235^th place

2reuters.com

49^th place

168^th place

2gov.uk

432^nd place

898^th place

2wikipedia.org

low place

2archive.org

6^th place

8^th place

2statnews.com

8,771^st place

low place

2washingtonpost.com

34^th place

157^th place

2modernatx.com

low place

2science.org

1,160^th place

3,413^th place

1handle.net

102^nd place

163^rd place

1ugent.be

3,695^th place

3,917^th place

1phgfoundation.org

low place

1theguardian.com

12^th place

64^th place

1nature.com

234^th place

113^th place

1wipo.int

1,462^nd place

791^st place

1france24.com

481^st place

1,182^nd place

1biocentury.com

low place

1prnewswire.com

406^th place

472^nd place

1bbc.com

20^th place

94^th place

1stanford.edu

179^th place

212^th place

1immune.org.nz

low place

1acs.org

1,248^th place

525^th place

1marketwatch.com

1,303^rd place

4,107^th place

1chemistryworld.com

low place

1cnn.com

28^th place

97^th place

1usatoday.com

41^st place

158^th place

1wsj.com

79^th place

313^th place

1businessinsider.com

140^th place

419^th place

1ctvnews.ca

768^th place

4,409^th place

1cvdvaccine-us.com

low place

1npr.org

92^nd place

346^th place

1nytimes.com

7^th place

32^nd place

1ft.com

210^th place

725^th place

1the-scientist.com

7,827^th place

3,913^th place

1bbc.co.uk

8^th place

31^st place

1telegraph.co.uk

30^th place

131^st place

1pipelinereview.com

low place

acs.org

cen.acs.org

Cross R (6 de marzo de 2021). "Without these lipid shells, there would be no mRNA vaccines for COVID-19". Chemical & Engineering News (American Chemical Society). Arquivado dende o orixinal o 5 de marzo de 2021. Consultado o 6 de marzo de 2021.

archive.org

Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, Liljeström P (decembro de 1994). "Self-replicating Semliki Forest virus RNA as recombinant vaccine". Vaccine 12 (16): 1510–14. PMID 7879415. doi:10.1016/0264-410x(94)90074-4.
Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljeström P (xuño de 1998). "Enhancing immune responses using suicidal DNA vaccines". Nature Biotechnology 16 (6): 562–65. PMID 9624688. doi:10.1038/nbt0698-562.

bbc.co.uk

Carmichael F, Goodman J (2 de decembro de 2020). "Vaccine rumours debunked: Microchips, 'altered DNA' and more" (Reality Check). BBC. Arquivado dende o orixinal o 13 de marzo de 2021. Consultado o 10 de decembro de 2020.

bbc.com

Roberts M (2 decembro de 2020). "Covid Pfizer vaccine approved for use next week in UK". BBC News. Arquivado dende o orixinal o 2 de decembro de 2020. Consultado o 2 de decembro de 2020.

biocentury.com

Usdin S (19 de marzo de 2020). "DARPA's gambles might have created the best hopes for stopping COVID-19". BioCentury. Arquivado dende o orixinal o 18 de xuño de 2021. Consultado o 19 de xuño de 2021.

businessinsider.com

Neilson S, Dunn A, Bendix A (26 de novembro de 2020). "Moderna's groundbreaking coronavirus vaccine was designed in just 2 days". Business Insider. Arquivado dende o orixinal o 11 de xaneiro de 2021. Consultado o 28 de novembro de 2020.

cdc.gov

Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (decembro de 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020" (PDF). MMWR Morb Mortal Wkly Rep 69 (50): 1922–24. PMC 7745957. PMID 33332292. doi:10.15585/mmwr.mm6950e2. Arquivado dende o orixinal (PDF) o 19 de decembro de 2020. Consultado o 7 de febreiro de 2021.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (xaneiro de 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020" (PDF). MMWR Morb Mortal Wkly Rep 69 (5152): 1653–56. PMC 9191904. PMID 33382675. doi:10.15585/mmwr.mm695152e1. Arquivado dende o orixinal (PDF) o 9 de febreiro de 2021. Consultado o 7 de febreiro de 2021.
"COVID-19 and Your Health". Centers for Disease Control and Prevention. 11 de febreiro de 2020. Arquivado dende o orixinal o 3 de marzo de 2021. Consultado o 26 de novembro de 2020.

chemistryworld.com

King A (23 de marzo de 2021). "Why manufacturing Covid vaccines at scale is hard". Chemistry World (Royal Society of Chemistry). Arquivado dende o orixinal o 24 de marzo de 2021. Consultado o 26 de marzo de 2021.

cnn.com

Sealy A (2 de abril de 2021). "Manufacturing moonshot: How Pfizer makes its millions of Covid-19 vaccine doses". CNN. Arquivado dende o orixinal o 1 de abril de 2021. Consultado o 3 de abril de 2021.

ctvnews.ca

Rabson M (27 de febreiro de 2021). "From science to syringe: COVID-19 vaccines are miracles of science and supply chains". CTV News (Bell Media). Arquivado dende o orixinal o 27 de febreiro de 2021. Consultado o 28 de febreiro de 2021.

cvdvaccine-us.com

"Pfizer-BioNTech COVID-19 Vaccine Vaccination Storage & Dry Ice Safety Handling". Pfizer. Arquivado dende o orixinal o 24 de xaneiro de 2021. Consultado o 17 de decembro de 2020.

doi.org

dx.doi.org

Park KS, Sun X, Aikins ME, Moon JJ (decembro de 2020). "Non-viral COVID-19 vaccine delivery systems". Advanced Drug Delivery Reviews 169: 137–51. PMC 7744276. PMID 33340620. doi:10.1016/j.addr.2020.12.008.
Kowalski PS, Rudra A, Miao L, Anderson DG (abril de 2019). "Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery". Mol Ther 27 (4): 710–28. PMC 6453548. PMID 30846391. doi:10.1016/j.ymthe.2019.02.012.
Verbeke R, Lentacker I, De Smedt SC, Dewitte H (outubro de 2019). "Three decades of messenger RNA vaccine development". Nano Today 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. Arquivado dende o orixinal o 11 de xaneiro de 2021. Consultado o 8 de decembro de 2020.
Pardi N, Hogan MJ, Porter FW, Weissman D (abril de 2018). "mRNA vaccines — a new era in vaccinology". Nature Reviews Drug Discovery 17 (4): 261–279. ISSN 1474-1784. PMC 5906799. PMID 29326426. doi:10.1038/nrd.2017.243.
Kramps T, Elders K (2017). "Introduction to RNA Vaccines". RNA Vaccines: Methods and Protocols. Methods in Molecular Biology 1499. pp. 1–11. ISBN 978-1-4939-6479-6. PMID 27987140. doi:10.1007/978-1-4939-6481-9_1.
Crommelin DJ, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E (marzo de 2021). "Addressing the Cold Reality of mRNA Vaccine Stability". Journal of Pharmaceutical Sciences 110 (3): 997–1001. ISSN 0022-3549. PMC 7834447. PMID 33321139. doi:10.1016/j.xphs.2020.12.006.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (decembro de 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020" (PDF). MMWR Morb Mortal Wkly Rep 69 (50): 1922–24. PMC 7745957. PMID 33332292. doi:10.15585/mmwr.mm6950e2. Arquivado dende o orixinal (PDF) o 19 de decembro de 2020. Consultado o 7 de febreiro de 2021.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (xaneiro de 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020" (PDF). MMWR Morb Mortal Wkly Rep 69 (5152): 1653–56. PMC 9191904. PMID 33382675. doi:10.15585/mmwr.mm695152e1. Arquivado dende o orixinal (PDF) o 9 de febreiro de 2021. Consultado o 7 de febreiro de 2021.
Xu S, Yang K, Li R, Zhang L (setembro de 2020). "mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection". International Journal of Molecular Sciences 21 (18): 6582. PMC 7554980. PMID 32916818. doi:10.3390/ijms21186582 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7554980 |PMC= sen título (Axuda). Initiation of cationic lipid-mediated mrna transfection; Concept proposal of mRNA-based drugs
Malone RW, Felgner PL, Verma IM (agosto de 1989). "Cationic liposome-mediated RNA transfection". Proceedings of the National Academy of Sciences of the United States of America 86 (16): 6077–81. Bibcode:1989PNAS...86.6077M. PMC 297778. PMID 2762315. doi:10.1073/pnas.86.16.6077 //www.ncbi.nlm.nih.gov/pmc/articles/PMC297778 |PMC= sen título (Axuda).
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (marzo de 1990). "Direct gene transfer into mouse muscle in vivo". Science 247 (4949 Pt 1): 1465–8. Bibcode:1990Sci...247.1465W. PMID 1690918. doi:10.1126/science.1690918.
Xu S, Yang K, Li R, Zhang L (setembro de 2020). "mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection". International Journal of Molecular Sciences 21 (18): 6582. PMC 7554980. PMID 32916818. doi:10.3390/ijms21186582 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7554980 |PMC= sen título (Axuda). Concept proposal of mRNA vaccines (1990)
Pascolo S (agosto de 2004). "Messenger RNA-based vaccines". Expert Opinion on Biological Therapy 4 (8): 1285–94. PMID 15268662. doi:10.1517/14712598.4.8.1285.
Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, Guillet JG, et al. (xullo de 1993). "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA". European Journal of Immunology 23 (7): 1719–22. PMID 8325342. doi:10.1002/eji.1830230749.
Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, Liljeström P (decembro de 1994). "Self-replicating Semliki Forest virus RNA as recombinant vaccine". Vaccine 12 (16): 1510–14. PMID 7879415. doi:10.1016/0264-410x(94)90074-4.
Kallen KJ, Theß A (xaneiro de 2014). "A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs". Therapeutic Advances in Vaccines 2 (1): 10–31. PMC 3991152. PMID 24757523. doi:10.1177/2051013613508729.
Sahin U, Karikó K, Türeci Ö (outubro de 2014). "mRNA-based therapeutics — developing a new class of drugs". Nature Reviews Drug Discovery 13 (10): 759–80. ISSN 1474-1784. PMID 25233993. doi:10.1038/nrd4278.
Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. (febreiro de 2002). "Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors". The Journal of Clinical Investigation 109 (3): 409–17. ISSN 0021-9738. PMC 150859. PMID 11828001. doi:10.1172/JCI14364.
Karikó K, Buckstein M, Ni H, Weissman D (agosto de 2005). "Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA". Immunity 23 (2): 165–75. PMID 16111635. doi:10.1016/j.immuni.2005.06.008.
Blakney AK, Ip S, Geall AJ (xaneiro de 2021). "An Update on Self-Amplifying mRNA Vaccine Development". Vaccines 9 (2): 97. PMC 7911542. PMID 33525396. doi:10.3390/vaccines9020097 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7911542 |PMC= sen título (Axuda).
Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, et al. (febreiro-marzo de 2008). "Results of the first phase I/II clinical vaccination trial with direct injection of mRNA". Journal of Immunotherapy 31 (2): 180–8. PMID 18481387. doi:10.1097/CJI.0b013e31815ce501.
Dolgin E (setembro de 2021). "The tangled history of mRNA vaccines". Nature 597 (7876): 318–24. Bibcode:2021Natur.597..318D. ISSN 0028-0836. PMID 34522017. doi:10.1038/d41586-021-02483-w.
Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. (setembro de 2017). "Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial". The Lancet 390 (10101): 1511–20. PMID 28754494. doi:10.1016/S0140-6736(17)31665-3.
Dolgin E (novembro de 2021). "mRNA flu shots move into trials". Nature Reviews Drug Discovery 20 (11): 801–3. PMID 34635829. doi:10.1038/d41573-021-00176-7.
Hou X, Zaks T, Langer R, Dong Y (agosto de 2021). "Lipid nanoparticles for mRNA delivery". Nature Reviews Materials 6 (12): 1078–94. Bibcode:2021NatRM...6.1078H. ISSN 2058-8437. PMC 8353930. PMID 34394960. doi:10.1038/s41578-021-00358-0 //www.ncbi.nlm.nih.gov/pmc/articles/PMC8353930 |PMC= sen título (Axuda).
Ball P (xaneiro de 2021). "The lightning-fast quest for COVID vaccines — and what it means for other diseases". Nature 589 (7840): 16–18. Bibcode:2021Natur.589...16B. PMID 33340018. doi:10.1038/d41586-020-03626-1.
Wherry EJ, Jaffee EM, Warren N, D'Souza G, Ribas A (abril de 2021). "How Did We Get a COVID-19 Vaccine in Less Than 1 Year?". Clinical Cancer Research 27 (8): 2136–38. ISSN 1078-0432. PMC 8052930. PMID 33542081. doi:10.1158/1078-0432.CCR-21-0079.
Batty CJ, Heise MT, Bachelder EM, Ainslie KM (decembro de 2020). "Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection". Advanced Drug Delivery Reviews 169: 168–89. PMC 7733686. PMID 33316346. doi:10.1016/j.addr.2020.12.006.
Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO (febreiro de 2021). "SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates". npj Vaccines 6 (1): 28. PMC 7900244. PMID 33619260. doi:10.1038/s41541-021-00292-w.
Bull JJ, Nuismer SL, Antia R (xullo de 2019). "Recombinant vector vaccine evolution". PLOS Computational Biology 15 (7): e1006857. Bibcode:2019PLSCB..15E6857B. PMC 6668849. PMID 31323032. doi:10.1371/journal.pcbi.1006857.
Hajj KA, Whitehead KA (setembro de 2017). "Tools for translation: non-viral materials for therapeutic mRNA delivery". Nature Reviews Materials 2 (10): 17056. Bibcode:2017NatRM...217056H. doi:10.1038/natrevmats.2017.56.
Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ (novembro de 2012). "Developing mRNA-vaccine technologies". RNA Biology 9 (11): 1319–30. PMC 3597572. PMID 23064118. doi:10.4161/rna.22269.
Anand P, Stahel VP (maio de 2021). "Review the safety of Covid-19 mRNA vaccines: a review". Patient Safety in Surgery 15 (1): 20. PMC 8087878. PMID 33933145. doi:10.1186/s13037-021-00291-9.
Xu S, Yang K, Li R, Zhang L (setembro de 2020). "mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection". International Journal of Molecular Sciences 21 (18): 6582. PMC 7554980. PMID 32916818. doi:10.3390/ijms21186582 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7554980 |PMC= sen título (Axuda).
Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R (2016). "mRNA Cancer Vaccines". Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les Recherches Sur le Cancer. Recent Results in Cancer Research 209: 61–85. ISBN 978-3-319-42932-8. PMID 28101688. doi:10.1007/978-3-319-42934-2_5.
Jackson NA, Kester KE, Casimiro D, Gurunathan S, DeRosa F (febreiro de 2020). "The promise of mRNA vaccines: a biotech and industrial perspective". npj Vaccines 5 (1): 11. ISSN 2059-0105. PMC 7000814. PMID 32047656. doi:10.1038/s41541-020-0159-8.
Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K (febreiro de 2015). "mRNA-based dendritic cell vaccines". Expert Review of Vaccines 14 (2): 161–76. PMID 25196947. doi:10.1586/14760584.2014.957684.
Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, et al. (novembro de 2010). "Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity". Cancer Research 70 (22): 9031–40. PMID 21045153. doi:10.1158/0008-5472.can-10-0699.
Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, Pascolo S (agosto de 2007). "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent". Gene Therapy 14 (15): 1175–80. PMID 17476302. doi:10.1038/sj.gt.3302964.
Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Dam TC, Verdurmen WP, et al. (xullo de 2011). "Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway". RNA Biology 8 (4): 627–36. PMID 21654214. doi:10.4161/rna.8.4.15394.
Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, et al. (xuño de 2009). "Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients". Journal of Immunotherapy 32 (5): 498–507. PMID 19609242. doi:10.1097/CJI.0b013e3181a00068.
Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X (febreiro de 2021). "mRNA vaccine: a potential therapeutic strategy". Molecular Cancer 20 (1): 33. PMC 7884263. PMID 33593376. doi:10.1186/s12943-021-01311-z.
Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D (maio de 2016). "mRNA vaccine delivery using lipid nanoparticles". Therapeutic Delivery 7 (5): 319–34. PMC 5439223. PMID 27075952. doi:10.4155/tde-2016-0006.
Paunovska K, Sago CD, Monaco CM, Hudson WH, Castro MG, Rudoltz TG, et al. (marzo de 2018). "A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation". Nano Letters 18 (3): 2148–57. Bibcode:2018NanoL..18.2148P. PMC 6054134. PMID 29489381. doi:10.1021/acs.nanolett.8b00432.
Lundstrom K (marzo de 2019). "RNA Viruses as Tools in Gene Therapy and Vaccine Development". Genes 10 (3): 189. PMC 6471356. PMID 30832256. doi:10.3390/genes10030189.
Huang TT, Parab S, Burnett R, Diago O, Ostertag D, Hofman FM, et al. (febreiro de 2015). "Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model". Human Gene Therapy 26 (2): 82–93. PMC 4326030. PMID 25419577. doi:10.1089/hum.2014.100.
Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R, Perdue ML (decembro de 2000). "Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses". Virology 278 (1): 55–59. PMID 11112481. doi:10.1006/viro.2000.0635.
Geisbert TW, Feldmann H (novembro de 2011). "Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections". The Journal of Infectious Diseases 204 (Suppl 3): S1075–81. PMC 3218670. PMID 21987744. doi:10.1093/infdis/jir349.
Dolgin E (novembro de 2020). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature Biotechnology. PMID 33239758. doi:10.1038/d41587-020-00022-y.
Karikó K, Muramatsu H, Ludwig J, Weissman D (novembro de 2011). "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA". Nucleic Acids Research 39 (21): e142. PMC 3241667. PMID 21890902. doi:10.1093/nar/gkr695.
Pardi N, Weissman D (17 de decembro de 2016). "Nucleoside Modified mRNA Vaccines for Infectious Diseases". RNA Vaccines. Methods in Molecular Biology 1499. Springer New York. pp. 109–21. ISBN 978-1-4939-6479-6. PMID 27987145. doi:10.1007/978-1-4939-6481-9_6.
Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljeström P (xuño de 1998). "Enhancing immune responses using suicidal DNA vaccines". Nature Biotechnology 16 (6): 562–65. PMID 9624688. doi:10.1038/nbt0698-562.
Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, et al. (febreiro de 2018). "Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses". Molecular Therapy 26 (2): 446–55. PMC 5835025. PMID 29275847. doi:10.1016/j.ymthe.2017.11.017.
Wadman M (novembro de 2020). "Public needs to prep for vaccine side effects". Science 370 (6520): 1022. PMID 33243869. doi:10.1126/science.370.6520.1022.
Skalka AM (2014). "Retroviral DNA Transposition: Themes and Variations". Microbiology Spectrum 2 (5): 1101–23. ISBN 9781555819200. PMC 4383315. PMID 25844274. doi:10.1128/microbiolspec.MDNA3-0005-2014.
Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ (xuño de 2014). "Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines". Expert Opin Drug Deliv 11 (6): 885–99. PMID 24665982. doi:10.1517/17425247.2014.901308.
Versteeg L, Almutairi MM, Hotez PJ, Pollet J (setembro de 2019). "Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections". Vaccines 7 (4): 122. PMC 6963228. PMID 31547081. doi:10.3390/vaccines7040122 //www.ncbi.nlm.nih.gov/pmc/articles/PMC6963228 |PMC= sen título (Axuda).
Bloom K, van den Berg F, Arbuthnot P (abril de 2021). "Self-amplifying RNA vaccines for infectious diseases". Gene Therapy 28 (3–4): 117–129. PMC 7580817. PMID 33093657. doi:10.1038/s41434-020-00204-y.

fda.gov

"FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Nota de prensa). 11 de decembro de 2020. Arquivado dende o orixinal o 31 de xaneiro de 2021. Consultado o 6 de febreiro de 2021.
"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Nota de prensa). 18 de decembro de 2020. Arquivado dende o orixinal o 19 de decembro de 2020. Consultado o 21 de decembro de 2020.
Office of the Commissioner (18 de decembro de 2020). "Pfizer-BioNTech COVID-19 Vaccine". FDA. Arquivado dende o orixinal o 14 de xaneiro de 2021. Consultado o 21 de decembro de 2020.
"Fact Sheet for Healthcare Providers Administering Vaccine". ModernaTX, Inc. Arquivado dende o orixinal (PDF) o 28 de xsneiro de 2021. Consultado o 21 de decembro de 2020.

france24.com

"BioNTech's founders: scientist couple in global spotlight". France 24. 13 de novembro de 2020. Arquivado dende o orixinal o 14 de febreiro de 2021. Consultado o 31 de xullo de 2021.

ft.com

Kuchler H (30 de setembro de 2020). "Pfizer boss warns on risk of fast-tracking vaccines". Financial Times. Arquivado dende o orixinal o 18 de novembro de 2020. Consultado o 21 de novembro de 2020.

gov.uk

"UK authorises Pfizer/BioNTech COVID-19 vaccine" (Nota de prensa). Department of Health and Social Care. 2 de decembro de 2020. Arquivado dende o orixinal o 2 de decembro de 2020. Consultado o 2 de decembro de 2020.
"Conditions of Authorisation for Pfizer/BioNTech COVID-19 Vaccine" (Decision). Medicines & Healthcare Products Regulatory Agency. 8 de decembro de 2020. Arquivado dende o orixinal o 7 de decembro de 2020. Consultado o 10 de decembro de 2020.

handle.net

hdl.handle.net

Verbeke R, Lentacker I, De Smedt SC, Dewitte H (outubro de 2019). "Three decades of messenger RNA vaccine development". Nano Today 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. Arquivado dende o orixinal o 11 de xaneiro de 2021. Consultado o 8 de decembro de 2020.

harvard.edu

adsabs.harvard.edu

Malone RW, Felgner PL, Verma IM (agosto de 1989). "Cationic liposome-mediated RNA transfection". Proceedings of the National Academy of Sciences of the United States of America 86 (16): 6077–81. Bibcode:1989PNAS...86.6077M. PMC 297778. PMID 2762315. doi:10.1073/pnas.86.16.6077 //www.ncbi.nlm.nih.gov/pmc/articles/PMC297778 |PMC= sen título (Axuda).
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (marzo de 1990). "Direct gene transfer into mouse muscle in vivo". Science 247 (4949 Pt 1): 1465–8. Bibcode:1990Sci...247.1465W. PMID 1690918. doi:10.1126/science.1690918.
Dolgin E (setembro de 2021). "The tangled history of mRNA vaccines". Nature 597 (7876): 318–24. Bibcode:2021Natur.597..318D. ISSN 0028-0836. PMID 34522017. doi:10.1038/d41586-021-02483-w.
Hou X, Zaks T, Langer R, Dong Y (agosto de 2021). "Lipid nanoparticles for mRNA delivery". Nature Reviews Materials 6 (12): 1078–94. Bibcode:2021NatRM...6.1078H. ISSN 2058-8437. PMC 8353930. PMID 34394960. doi:10.1038/s41578-021-00358-0 //www.ncbi.nlm.nih.gov/pmc/articles/PMC8353930 |PMC= sen título (Axuda).
Ball P (xaneiro de 2021). "The lightning-fast quest for COVID vaccines — and what it means for other diseases". Nature 589 (7840): 16–18. Bibcode:2021Natur.589...16B. PMID 33340018. doi:10.1038/d41586-020-03626-1.
Bull JJ, Nuismer SL, Antia R (xullo de 2019). "Recombinant vector vaccine evolution". PLOS Computational Biology 15 (7): e1006857. Bibcode:2019PLSCB..15E6857B. PMC 6668849. PMID 31323032. doi:10.1371/journal.pcbi.1006857.
Hajj KA, Whitehead KA (setembro de 2017). "Tools for translation: non-viral materials for therapeutic mRNA delivery". Nature Reviews Materials 2 (10): 17056. Bibcode:2017NatRM...217056H. doi:10.1038/natrevmats.2017.56.
Paunovska K, Sago CD, Monaco CM, Hudson WH, Castro MG, Rudoltz TG, et al. (marzo de 2018). "A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation". Nano Letters 18 (3): 2148–57. Bibcode:2018NanoL..18.2148P. PMC 6054134. PMID 29489381. doi:10.1021/acs.nanolett.8b00432.

immune.org.nz

"Vaccine components". Immunisation Advisory Centre. 22 de setembro de 2016. Arquivado dende o orixinal o 26 de xsneiro de 2021. Consultado o 20 de decembro de 2020.

marketwatch.com

Lowe D (3 de febreiro de 2021). "Opinion: A straightforward explanation why more COVID-19 vaccines can't be produced with help from 'dozens' of companies". MarketWatch. Arquivado dende o orixinal o 5 de febreiro de 2021. Consultado o 5 de febreiro de 2021.

modernatx.com

investors.modernatx.com

"Moderna Announces Its Global Public Health Strategy". investors.modernatx.com (en inglés). Arquivado dende o orixinal o 16 de marzo de 2022. Consultado o 15 de marzo de 2022.
"Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures". NPR.org. Arquivado dende o orixinal o 16 de novembro de 2020. Consultado o 18 de novembro de 2020.

nature.com

May M (31 de maio de 2021). "After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases". Nature. Arquivado dende o orixinal o 13 de outubro de 2021. Consultado o 31 de xullo de 2021. Cando se estaban testando a ampla variedade de vacinas contra a COVID-19 en ensaios clínicos, só uns poucos expertos esperaban que a tecnoloxía non probada do ARNm fose a estrela. En 10 meses, as vacinas de ARNm eran tanto as primeiras en ser aprobadas coma as máis efectivas. Aínda que estas son as primeiras vacinas de ARNm que se aprobaron, a historia das vacinas de ARNm empeza hai máis de 30 anos, con moitas fochas na estrada por diante. En 1990, o último científico físico Jon Wolff e os seus colegas da Universidade de Wisconsin inxectaron ARNm en ratos, que causou que as células do rato producisen as proteínas codificadas. En moitos aspectos, ese traballo serviu como un primeiro paso cara a facer unha vacina a partir de ARNm, pero había un longo camiño que percorrer, e aínda o hai, para moitas aplicacións.

nih.gov

ncbi.nlm.nih.gov

Park KS, Sun X, Aikins ME, Moon JJ (decembro de 2020). "Non-viral COVID-19 vaccine delivery systems". Advanced Drug Delivery Reviews 169: 137–51. PMC 7744276. PMID 33340620. doi:10.1016/j.addr.2020.12.008.
Kowalski PS, Rudra A, Miao L, Anderson DG (abril de 2019). "Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery". Mol Ther 27 (4): 710–28. PMC 6453548. PMID 30846391. doi:10.1016/j.ymthe.2019.02.012.
Pardi N, Hogan MJ, Porter FW, Weissman D (abril de 2018). "mRNA vaccines — a new era in vaccinology". Nature Reviews Drug Discovery 17 (4): 261–279. ISSN 1474-1784. PMC 5906799. PMID 29326426. doi:10.1038/nrd.2017.243.
Kramps T, Elders K (2017). "Introduction to RNA Vaccines". RNA Vaccines: Methods and Protocols. Methods in Molecular Biology 1499. pp. 1–11. ISBN 978-1-4939-6479-6. PMID 27987140. doi:10.1007/978-1-4939-6481-9_1.
Crommelin DJ, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E (marzo de 2021). "Addressing the Cold Reality of mRNA Vaccine Stability". Journal of Pharmaceutical Sciences 110 (3): 997–1001. ISSN 0022-3549. PMC 7834447. PMID 33321139. doi:10.1016/j.xphs.2020.12.006.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (decembro de 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020" (PDF). MMWR Morb Mortal Wkly Rep 69 (50): 1922–24. PMC 7745957. PMID 33332292. doi:10.15585/mmwr.mm6950e2. Arquivado dende o orixinal (PDF) o 19 de decembro de 2020. Consultado o 7 de febreiro de 2021.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (xaneiro de 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020" (PDF). MMWR Morb Mortal Wkly Rep 69 (5152): 1653–56. PMC 9191904. PMID 33382675. doi:10.15585/mmwr.mm695152e1. Arquivado dende o orixinal (PDF) o 9 de febreiro de 2021. Consultado o 7 de febreiro de 2021.
Xu S, Yang K, Li R, Zhang L (setembro de 2020). "mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection". International Journal of Molecular Sciences 21 (18): 6582. PMC 7554980. PMID 32916818. doi:10.3390/ijms21186582 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7554980 |PMC= sen título (Axuda). Initiation of cationic lipid-mediated mrna transfection; Concept proposal of mRNA-based drugs
Malone RW, Felgner PL, Verma IM (agosto de 1989). "Cationic liposome-mediated RNA transfection". Proceedings of the National Academy of Sciences of the United States of America 86 (16): 6077–81. Bibcode:1989PNAS...86.6077M. PMC 297778. PMID 2762315. doi:10.1073/pnas.86.16.6077 //www.ncbi.nlm.nih.gov/pmc/articles/PMC297778 |PMC= sen título (Axuda).
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (marzo de 1990). "Direct gene transfer into mouse muscle in vivo". Science 247 (4949 Pt 1): 1465–8. Bibcode:1990Sci...247.1465W. PMID 1690918. doi:10.1126/science.1690918.
Xu S, Yang K, Li R, Zhang L (setembro de 2020). "mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection". International Journal of Molecular Sciences 21 (18): 6582. PMC 7554980. PMID 32916818. doi:10.3390/ijms21186582 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7554980 |PMC= sen título (Axuda). Concept proposal of mRNA vaccines (1990)
Pascolo S (agosto de 2004). "Messenger RNA-based vaccines". Expert Opinion on Biological Therapy 4 (8): 1285–94. PMID 15268662. doi:10.1517/14712598.4.8.1285.
Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, Guillet JG, et al. (xullo de 1993). "Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA". European Journal of Immunology 23 (7): 1719–22. PMID 8325342. doi:10.1002/eji.1830230749.
Zhou X, Berglund P, Rhodes G, Parker SE, Jondal M, Liljeström P (decembro de 1994). "Self-replicating Semliki Forest virus RNA as recombinant vaccine". Vaccine 12 (16): 1510–14. PMID 7879415. doi:10.1016/0264-410x(94)90074-4.
Kallen KJ, Theß A (xaneiro de 2014). "A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs". Therapeutic Advances in Vaccines 2 (1): 10–31. PMC 3991152. PMID 24757523. doi:10.1177/2051013613508729.
Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, et al. (abril de 1995). "Characterization of a messenger RNA polynucleotide vaccine vector". Cancer Research 55 (7): 1397–400. PMID 7882341.
Sahin U, Karikó K, Türeci Ö (outubro de 2014). "mRNA-based therapeutics — developing a new class of drugs". Nature Reviews Drug Discovery 13 (10): 759–80. ISSN 1474-1784. PMID 25233993. doi:10.1038/nrd4278.
Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. (febreiro de 2002). "Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors". The Journal of Clinical Investigation 109 (3): 409–17. ISSN 0021-9738. PMC 150859. PMID 11828001. doi:10.1172/JCI14364.
Karikó K, Buckstein M, Ni H, Weissman D (agosto de 2005). "Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA". Immunity 23 (2): 165–75. PMID 16111635. doi:10.1016/j.immuni.2005.06.008.
Blakney AK, Ip S, Geall AJ (xaneiro de 2021). "An Update on Self-Amplifying mRNA Vaccine Development". Vaccines 9 (2): 97. PMC 7911542. PMID 33525396. doi:10.3390/vaccines9020097 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7911542 |PMC= sen título (Axuda).
Weide B, Carralot JP, Reese A, Scheel B, Eigentler TK, Hoerr I, et al. (febreiro-marzo de 2008). "Results of the first phase I/II clinical vaccination trial with direct injection of mRNA". Journal of Immunotherapy 31 (2): 180–8. PMID 18481387. doi:10.1097/CJI.0b013e31815ce501.
Dolgin E (setembro de 2021). "The tangled history of mRNA vaccines". Nature 597 (7876): 318–24. Bibcode:2021Natur.597..318D. ISSN 0028-0836. PMID 34522017. doi:10.1038/d41586-021-02483-w.
Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. (setembro de 2017). "Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial". The Lancet 390 (10101): 1511–20. PMID 28754494. doi:10.1016/S0140-6736(17)31665-3.
Dolgin E (novembro de 2021). "mRNA flu shots move into trials". Nature Reviews Drug Discovery 20 (11): 801–3. PMID 34635829. doi:10.1038/d41573-021-00176-7.
Hou X, Zaks T, Langer R, Dong Y (agosto de 2021). "Lipid nanoparticles for mRNA delivery". Nature Reviews Materials 6 (12): 1078–94. Bibcode:2021NatRM...6.1078H. ISSN 2058-8437. PMC 8353930. PMID 34394960. doi:10.1038/s41578-021-00358-0 //www.ncbi.nlm.nih.gov/pmc/articles/PMC8353930 |PMC= sen título (Axuda).
Ball P (xaneiro de 2021). "The lightning-fast quest for COVID vaccines — and what it means for other diseases". Nature 589 (7840): 16–18. Bibcode:2021Natur.589...16B. PMID 33340018. doi:10.1038/d41586-020-03626-1.
Wherry EJ, Jaffee EM, Warren N, D'Souza G, Ribas A (abril de 2021). "How Did We Get a COVID-19 Vaccine in Less Than 1 Year?". Clinical Cancer Research 27 (8): 2136–38. ISSN 1078-0432. PMC 8052930. PMID 33542081. doi:10.1158/1078-0432.CCR-21-0079.
Batty CJ, Heise MT, Bachelder EM, Ainslie KM (decembro de 2020). "Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection". Advanced Drug Delivery Reviews 169: 168–89. PMC 7733686. PMID 33316346. doi:10.1016/j.addr.2020.12.006.
Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO (febreiro de 2021). "SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates". npj Vaccines 6 (1): 28. PMC 7900244. PMID 33619260. doi:10.1038/s41541-021-00292-w.
Bull JJ, Nuismer SL, Antia R (xullo de 2019). "Recombinant vector vaccine evolution". PLOS Computational Biology 15 (7): e1006857. Bibcode:2019PLSCB..15E6857B. PMC 6668849. PMID 31323032. doi:10.1371/journal.pcbi.1006857.
Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ (novembro de 2012). "Developing mRNA-vaccine technologies". RNA Biology 9 (11): 1319–30. PMC 3597572. PMID 23064118. doi:10.4161/rna.22269.
Anand P, Stahel VP (maio de 2021). "Review the safety of Covid-19 mRNA vaccines: a review". Patient Safety in Surgery 15 (1): 20. PMC 8087878. PMID 33933145. doi:10.1186/s13037-021-00291-9.
Xu S, Yang K, Li R, Zhang L (setembro de 2020). "mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection". International Journal of Molecular Sciences 21 (18): 6582. PMC 7554980. PMID 32916818. doi:10.3390/ijms21186582 //www.ncbi.nlm.nih.gov/pmc/articles/PMC7554980 |PMC= sen título (Axuda).
Fiedler K, Lazzaro S, Lutz J, Rauch S, Heidenreich R (2016). "mRNA Cancer Vaccines". Recent Results in Cancer Research. Fortschritte der Krebsforschung. Progres dans les Recherches Sur le Cancer. Recent Results in Cancer Research 209: 61–85. ISBN 978-3-319-42932-8. PMID 28101688. doi:10.1007/978-3-319-42934-2_5.
Jackson NA, Kester KE, Casimiro D, Gurunathan S, DeRosa F (febreiro de 2020). "The promise of mRNA vaccines: a biotech and industrial perspective". npj Vaccines 5 (1): 11. ISSN 2059-0105. PMC 7000814. PMID 32047656. doi:10.1038/s41541-020-0159-8.
Benteyn D, Heirman C, Bonehill A, Thielemans K, Breckpot K (febreiro de 2015). "mRNA-based dendritic cell vaccines". Expert Review of Vaccines 14 (2): 161–76. PMID 25196947. doi:10.1586/14760584.2014.957684.
Kreiter S, Selmi A, Diken M, Koslowski M, Britten CM, Huber C, et al. (novembro de 2010). "Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity". Cancer Research 70 (22): 9031–40. PMID 21045153. doi:10.1158/0008-5472.can-10-0699.
Probst J, Weide B, Scheel B, Pichler BJ, Hoerr I, Rammensee HG, Pascolo S (agosto de 2007). "Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent". Gene Therapy 14 (15): 1175–80. PMID 17476302. doi:10.1038/sj.gt.3302964.
Lorenz C, Fotin-Mleczek M, Roth G, Becker C, Dam TC, Verdurmen WP, et al. (xullo de 2011). "Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway". RNA Biology 8 (4): 627–36. PMID 21654214. doi:10.4161/rna.8.4.15394.
Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, et al. (xuño de 2009). "Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients". Journal of Immunotherapy 32 (5): 498–507. PMID 19609242. doi:10.1097/CJI.0b013e3181a00068.
Wang Y, Zhang Z, Luo J, Han X, Wei Y, Wei X (febreiro de 2021). "mRNA vaccine: a potential therapeutic strategy". Molecular Cancer 20 (1): 33. PMC 7884263. PMID 33593376. doi:10.1186/s12943-021-01311-z.
Reichmuth AM, Oberli MA, Jaklenec A, Langer R, Blankschtein D (maio de 2016). "mRNA vaccine delivery using lipid nanoparticles". Therapeutic Delivery 7 (5): 319–34. PMC 5439223. PMID 27075952. doi:10.4155/tde-2016-0006.
Paunovska K, Sago CD, Monaco CM, Hudson WH, Castro MG, Rudoltz TG, et al. (marzo de 2018). "A Direct Comparison of in Vitro and in Vivo Nucleic Acid Delivery Mediated by Hundreds of Nanoparticles Reveals a Weak Correlation". Nano Letters 18 (3): 2148–57. Bibcode:2018NanoL..18.2148P. PMC 6054134. PMID 29489381. doi:10.1021/acs.nanolett.8b00432.
Lundstrom K (marzo de 2019). "RNA Viruses as Tools in Gene Therapy and Vaccine Development". Genes 10 (3): 189. PMC 6471356. PMID 30832256. doi:10.3390/genes10030189.
Huang TT, Parab S, Burnett R, Diago O, Ostertag D, Hofman FM, et al. (febreiro de 2015). "Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model". Human Gene Therapy 26 (2): 82–93. PMC 4326030. PMID 25419577. doi:10.1089/hum.2014.100.
Schultz-Cherry S, Dybing JK, Davis NL, Williamson C, Suarez DL, Johnston R, Perdue ML (decembro de 2000). "Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses". Virology 278 (1): 55–59. PMID 11112481. doi:10.1006/viro.2000.0635.
Geisbert TW, Feldmann H (novembro de 2011). "Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections". The Journal of Infectious Diseases 204 (Suppl 3): S1075–81. PMC 3218670. PMID 21987744. doi:10.1093/infdis/jir349.
Dolgin E (novembro de 2020). "COVID-19 vaccines poised for launch, but impact on pandemic unclear". Nature Biotechnology. PMID 33239758. doi:10.1038/d41587-020-00022-y.
Karikó K, Muramatsu H, Ludwig J, Weissman D (novembro de 2011). "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA". Nucleic Acids Research 39 (21): e142. PMC 3241667. PMID 21890902. doi:10.1093/nar/gkr695.
Pardi N, Weissman D (17 de decembro de 2016). "Nucleoside Modified mRNA Vaccines for Infectious Diseases". RNA Vaccines. Methods in Molecular Biology 1499. Springer New York. pp. 109–21. ISBN 978-1-4939-6479-6. PMID 27987145. doi:10.1007/978-1-4939-6481-9_6.
Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljeström P (xuño de 1998). "Enhancing immune responses using suicidal DNA vaccines". Nature Biotechnology 16 (6): 562–65. PMID 9624688. doi:10.1038/nbt0698-562.
Vogel AB, Lambert L, Kinnear E, Busse D, Erbar S, Reuter KC, et al. (febreiro de 2018). "Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses". Molecular Therapy 26 (2): 446–55. PMC 5835025. PMID 29275847. doi:10.1016/j.ymthe.2017.11.017.
Wadman M (novembro de 2020). "Public needs to prep for vaccine side effects". Science 370 (6520): 1022. PMID 33243869. doi:10.1126/science.370.6520.1022.
Skalka AM (2014). "Retroviral DNA Transposition: Themes and Variations". Microbiology Spectrum 2 (5): 1101–23. ISBN 9781555819200. PMC 4383315. PMID 25844274. doi:10.1128/microbiolspec.MDNA3-0005-2014.
Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ (xuño de 2014). "Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines". Expert Opin Drug Deliv 11 (6): 885–99. PMID 24665982. doi:10.1517/17425247.2014.901308.
Versteeg L, Almutairi MM, Hotez PJ, Pollet J (setembro de 2019). "Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections". Vaccines 7 (4): 122. PMC 6963228. PMID 31547081. doi:10.3390/vaccines7040122 //www.ncbi.nlm.nih.gov/pmc/articles/PMC6963228 |PMC= sen título (Axuda).
Bloom K, van den Berg F, Arbuthnot P (abril de 2021). "Self-amplifying RNA vaccines for infectious diseases". Gene Therapy 28 (3–4): 117–129. PMC 7580817. PMID 33093657. doi:10.1038/s41434-020-00204-y.

npr.org

Simmons-Duffin S. "Why Does Pfizer's COVID-19 Vaccine Need To Be Kept Colder Than Antarctica?". NPR.org. Arquivado dende o orixinal o 1 de febreiro de 2021. Consultado o 18 de novembro de 2020.

nytimes.com

Thomas K (22 de outubro de 2020). "Experts Tell F.D.A. It Should Gather More Safety Data on Covid-19 Vaccines". New York Times. Arquivado dende o orixinal o 26 de xaneiro de 2021. Consultado o 21 de novembro de 2020.

phgfoundation.org

PHG Foundation (2019). "RNA vaccines: an introduction". University of Cambridge. Arquivado dende o orixinal o 6 de decembro de 2018. Consultado o 18 de novembro de 2020.

pipelinereview.com

"Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer". PipelineReview. 20 de setembro de 2021. Arquivado dende o orixinal o 22 de setembro de 2021. Consultado o 21 de setembro de 2021.

prnewswire.com

"DARPA Awards Moderna Therapeutics A Grant For Up To $25 Million To Develop Messenger RNA Therapeutics" (Nota de prensa). 2 de outubro de 2013. Arquivado dende o orixinal o 2 de xuño de 2021. Consultado o 31 de maio de 2021.

reuters.com

"Mexico to start late-stage clinical trial for China's mRNA COVID-19 vaccine". Reuters. 11 de maio de 2021. Arquivado dende o orixinal o 23 de agosto de 2021. Consultado o 19 de agosto de 2021.
Steenhuysen, Julie; Erman, Michael (8 de marzo de 2022). "Moderna plots vaccines against 15 pathogens with future pandemic potential". Reuters (en inglés). Arquivado dende o orixinal o 14 de marzo de 2022. Consultado o 15 de marzo de 2022.

science.org

"New crop of COVID-19 mRNA vaccines could be easier to store, cheaper to use". www.science.org (en inglés). Arquivado dende o orixinal o 5 de abril de 2022. Consultado o 6 de abril de 2022.
Lowe D (1 de marzo de 2021). "A Malaria Vaccine Candidate". Science Translational Medicine. Arquivado dende o orixinal o 6 de maio de 2021. Consultado o 7 de maio de 2021.

stanford.edu

scopeblog.stanford.edu

Goldman B (22 de decembro de 2020). "How do the new COVID-19 vaccines work?". Scope. Stanford Medicine. Arquivado dende o orixinal o 30 de xaneiro de 2021. Consultado o 28 de xaneiro de 2021.

statnews.com

Garade D (10 de novembro de 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". Stat. Arquivado dende o orixinal o 10 de novembro de 2020. Consultado o 16 de novembro de 2020.
Cooney E (1 de decembro de 2020). "How nanotechnology helps mRNA Covid-19 vaccines work". Stat. Arquivado dende o orixinal o 1 de decembro de 2020. Consultado o 3 de decembro de 2020.

telegraph.co.uk

Knapton, Sarah (20 de setembro de 2021). "First 'variant-proof' Covid vaccine starts trials in Manchester - Retired couple Andrew Clarke, 63, and his wife Helen, 64, from Bolton, became the first to receive the mRNA vaccine on Monday". The Daily Telegraph. Arquivado dende o orixinal o 20 de setembro de 2021. Consultado o 21 de setembro de 2021.

the-scientist.com

Kwon D (25 de novembro de 2020). "The Promise of mRNA Vaccines". The Scientist. Arquivado dende o orixinal o 22 de xaneiro de 2021. Consultado o 27 de novembro de 2020.

theguardian.com

Boseley S, Halliday J (2 de decembro de 2020). "UK approves Pfizer/BioNTech Covid vaccine for rollout next week". The Guardian. Arquivado dende o orixinal o 2 de decembro de 2020. Consultado o 2 de decembro de 2020.

ugent.be

biblio.ugent.be

Verbeke R, Lentacker I, De Smedt SC, Dewitte H (outubro de 2019). "Three decades of messenger RNA vaccine development". Nano Today 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. Arquivado dende o orixinal o 11 de xaneiro de 2021. Consultado o 8 de decembro de 2020.

usatoday.com

Weise E, Weintraub K (7 de febreiro de 2021). "Race to the Vaccine: A COVID-19 vaccine life cycle: from DNA to doses". USA Today (Gannett). Arquivado dende o orixinal o 25 de febreiro de 2021. Consultado o 24 de febreiro de 2021.

washingtonpost.com

Sonne P (30 de xullo de 2020). "How a secretive Pentagon agency seeded the ground for a rapid coronavirus cure". The Washington Post. Arquivado dende o orixinal o 2 de agosto de 2021. Consultado o 21 de xuño de 2021.
Rowland C (18 de febreiro de 2021). "Why grandparents can't find vaccines: Scarcity of niche biotech ingredients". The Washington Post. Arquivado dende o orixinal o 26 de febreiro de 2021. Consultado o 7 de marzo de 2021.

web.archive.org

Verbeke R, Lentacker I, De Smedt SC, Dewitte H (outubro de 2019). "Three decades of messenger RNA vaccine development". Nano Today 28: 100766. doi:10.1016/j.nantod.2019.100766. hdl:1854/LU-8628303. Arquivado dende o orixinal o 11 de xaneiro de 2021. Consultado o 8 de decembro de 2020.
PHG Foundation (2019). "RNA vaccines: an introduction". University of Cambridge. Arquivado dende o orixinal o 6 de decembro de 2018. Consultado o 18 de novembro de 2020.
"Mexico to start late-stage clinical trial for China's mRNA COVID-19 vaccine". Reuters. 11 de maio de 2021. Arquivado dende o orixinal o 23 de agosto de 2021. Consultado o 19 de agosto de 2021.
"UK authorises Pfizer/BioNTech COVID-19 vaccine" (Nota de prensa). Department of Health and Social Care. 2 de decembro de 2020. Arquivado dende o orixinal o 2 de decembro de 2020. Consultado o 2 de decembro de 2020.
Boseley S, Halliday J (2 de decembro de 2020). "UK approves Pfizer/BioNTech Covid vaccine for rollout next week". The Guardian. Arquivado dende o orixinal o 2 de decembro de 2020. Consultado o 2 de decembro de 2020.
"Conditions of Authorisation for Pfizer/BioNTech COVID-19 Vaccine" (Decision). Medicines & Healthcare Products Regulatory Agency. 8 de decembro de 2020. Arquivado dende o orixinal o 7 de decembro de 2020. Consultado o 10 de decembro de 2020.
"FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Nota de prensa). 11 de decembro de 2020. Arquivado dende o orixinal o 31 de xaneiro de 2021. Consultado o 6 de febreiro de 2021.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (decembro de 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020" (PDF). MMWR Morb Mortal Wkly Rep 69 (50): 1922–24. PMC 7745957. PMID 33332292. doi:10.15585/mmwr.mm6950e2. Arquivado dende o orixinal (PDF) o 19 de decembro de 2020. Consultado o 7 de febreiro de 2021.
"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Nota de prensa). 18 de decembro de 2020. Arquivado dende o orixinal o 19 de decembro de 2020. Consultado o 21 de decembro de 2020.
Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (xaneiro de 2021). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020" (PDF). MMWR Morb Mortal Wkly Rep 69 (5152): 1653–56. PMC 9191904. PMID 33382675. doi:10.15585/mmwr.mm695152e1. Arquivado dende o orixinal (PDF) o 9 de febreiro de 2021. Consultado o 7 de febreiro de 2021.
May M (31 de maio de 2021). "After COVID-19 successes, researchers push to develop mRNA vaccines for other diseases". Nature. Arquivado dende o orixinal o 13 de outubro de 2021. Consultado o 31 de xullo de 2021. Cando se estaban testando a ampla variedade de vacinas contra a COVID-19 en ensaios clínicos, só uns poucos expertos esperaban que a tecnoloxía non probada do ARNm fose a estrela. En 10 meses, as vacinas de ARNm eran tanto as primeiras en ser aprobadas coma as máis efectivas. Aínda que estas son as primeiras vacinas de ARNm que se aprobaron, a historia das vacinas de ARNm empeza hai máis de 30 anos, con moitas fochas na estrada por diante. En 1990, o último científico físico Jon Wolff e os seus colegas da Universidade de Wisconsin inxectaron ARNm en ratos, que causou que as células do rato producisen as proteínas codificadas. En moitos aspectos, ese traballo serviu como un primeiro paso cara a facer unha vacina a partir de ARNm, pero había un longo camiño que percorrer, e aínda o hai, para moitas aplicacións.
Patent: WO1990011092 Arquivado 14 de outubro de 2021 en Wayback Machine.; Inventors: Philip L. Felgner, Jon Asher Wolff, Gary H. Rhodes, Robert Wallace Malone, Dennis A. Carson; Assignees: Vical Inc., Wisconsin Alumni Research Foundation; Title: "Expression of Exogenous Polynucleotide Sequences in a Vertebrate Arquivado 9 de decembro de 2021 en Wayback Machine."; (Cita: "O presente invento relaciónase coa introdución de secuencias de ADN e ARN espidas nun vertebrado para conseguir a expresión controlada dun polipéptido. É útil en terapia xénica, vacinación e en calquera situación terapéutica na cal un polipéptido debería administrarse a células in vivo"; Exemplo 8: vacinación de ARNm de ratos para producir a proteína gpl20 do VIH); Data de prioridade: 21 de marzo de 1989; data de publicación: 4 de outubro de 1990.
"BioNTech's founders: scientist couple in global spotlight". France 24. 13 de novembro de 2020. Arquivado dende o orixinal o 14 de febreiro de 2021. Consultado o 31 de xullo de 2021.
Garade D (10 de novembro de 2020). "The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race". Stat. Arquivado dende o orixinal o 10 de novembro de 2020. Consultado o 16 de novembro de 2020.
Sonne P (30 de xullo de 2020). "How a secretive Pentagon agency seeded the ground for a rapid coronavirus cure". The Washington Post. Arquivado dende o orixinal o 2 de agosto de 2021. Consultado o 21 de xuño de 2021.
Usdin S (19 de marzo de 2020). "DARPA's gambles might have created the best hopes for stopping COVID-19". BioCentury. Arquivado dende o orixinal o 18 de xuño de 2021. Consultado o 19 de xuño de 2021.
"DARPA Awards Moderna Therapeutics A Grant For Up To $25 Million To Develop Messenger RNA Therapeutics" (Nota de prensa). 2 de outubro de 2013. Arquivado dende o orixinal o 2 de xuño de 2021. Consultado o 31 de maio de 2021.
"COVID-19 and Your Health". Centers for Disease Control and Prevention. 11 de febreiro de 2020. Arquivado dende o orixinal o 3 de marzo de 2021. Consultado o 26 de novembro de 2020.
"Moderna Announces Its Global Public Health Strategy". investors.modernatx.com (en inglés). Arquivado dende o orixinal o 16 de marzo de 2022. Consultado o 15 de marzo de 2022.
Steenhuysen, Julie; Erman, Michael (8 de marzo de 2022). "Moderna plots vaccines against 15 pathogens with future pandemic potential". Reuters (en inglés). Arquivado dende o orixinal o 14 de marzo de 2022. Consultado o 15 de marzo de 2022.
Roberts M (2 decembro de 2020). "Covid Pfizer vaccine approved for use next week in UK". BBC News. Arquivado dende o orixinal o 2 de decembro de 2020. Consultado o 2 de decembro de 2020.
Office of the Commissioner (18 de decembro de 2020). "Pfizer-BioNTech COVID-19 Vaccine". FDA. Arquivado dende o orixinal o 14 de xaneiro de 2021. Consultado o 21 de decembro de 2020.
Goldman B (22 de decembro de 2020). "How do the new COVID-19 vaccines work?". Scope. Stanford Medicine. Arquivado dende o orixinal o 30 de xaneiro de 2021. Consultado o 28 de xaneiro de 2021.
"Vaccine components". Immunisation Advisory Centre. 22 de setembro de 2016. Arquivado dende o orixinal o 26 de xsneiro de 2021. Consultado o 20 de decembro de 2020.
Cooney E (1 de decembro de 2020). "How nanotechnology helps mRNA Covid-19 vaccines work". Stat. Arquivado dende o orixinal o 1 de decembro de 2020. Consultado o 3 de decembro de 2020.
Cross R (6 de marzo de 2021). "Without these lipid shells, there would be no mRNA vaccines for COVID-19". Chemical & Engineering News (American Chemical Society). Arquivado dende o orixinal o 5 de marzo de 2021. Consultado o 6 de marzo de 2021.
Lowe D (3 de febreiro de 2021). "Opinion: A straightforward explanation why more COVID-19 vaccines can't be produced with help from 'dozens' of companies". MarketWatch. Arquivado dende o orixinal o 5 de febreiro de 2021. Consultado o 5 de febreiro de 2021.
King A (23 de marzo de 2021). "Why manufacturing Covid vaccines at scale is hard". Chemistry World (Royal Society of Chemistry). Arquivado dende o orixinal o 24 de marzo de 2021. Consultado o 26 de marzo de 2021.
Sealy A (2 de abril de 2021). "Manufacturing moonshot: How Pfizer makes its millions of Covid-19 vaccine doses". CNN. Arquivado dende o orixinal o 1 de abril de 2021. Consultado o 3 de abril de 2021.
Weise E, Weintraub K (7 de febreiro de 2021). "Race to the Vaccine: A COVID-19 vaccine life cycle: from DNA to doses". USA Today (Gannett). Arquivado dende o orixinal o 25 de febreiro de 2021. Consultado o 24 de febreiro de 2021.
Hopkins JS, Eastwood J, Moriarty D (3 de marzo de 2021). "mRNA Covid-19 Vaccines Are Fast to Make, but Hard to Scale". The Wall Street Journal. Arquivado dende o orixinal o 4 de abril de 2021. Consultado o 3 de abril de 2021.
Rowland C (18 de febreiro de 2021). "Why grandparents can't find vaccines: Scarcity of niche biotech ingredients". The Washington Post. Arquivado dende o orixinal o 26 de febreiro de 2021. Consultado o 7 de marzo de 2021.
Neilson S, Dunn A, Bendix A (26 de novembro de 2020). "Moderna's groundbreaking coronavirus vaccine was designed in just 2 days". Business Insider. Arquivado dende o orixinal o 11 de xaneiro de 2021. Consultado o 28 de novembro de 2020.
Rabson M (27 de febreiro de 2021). "From science to syringe: COVID-19 vaccines are miracles of science and supply chains". CTV News (Bell Media). Arquivado dende o orixinal o 27 de febreiro de 2021. Consultado o 28 de febreiro de 2021.
"Pfizer-BioNTech COVID-19 Vaccine Vaccination Storage & Dry Ice Safety Handling". Pfizer. Arquivado dende o orixinal o 24 de xaneiro de 2021. Consultado o 17 de decembro de 2020.
Simmons-Duffin S. "Why Does Pfizer's COVID-19 Vaccine Need To Be Kept Colder Than Antarctica?". NPR.org. Arquivado dende o orixinal o 1 de febreiro de 2021. Consultado o 18 de novembro de 2020.
"Fact Sheet for Healthcare Providers Administering Vaccine". ModernaTX, Inc. Arquivado dende o orixinal (PDF) o 28 de xsneiro de 2021. Consultado o 21 de decembro de 2020.
"Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures". NPR.org. Arquivado dende o orixinal o 16 de novembro de 2020. Consultado o 18 de novembro de 2020.
Thomas K (22 de outubro de 2020). "Experts Tell F.D.A. It Should Gather More Safety Data on Covid-19 Vaccines". New York Times. Arquivado dende o orixinal o 26 de xaneiro de 2021. Consultado o 21 de novembro de 2020.
Kuchler H (30 de setembro de 2020). "Pfizer boss warns on risk of fast-tracking vaccines". Financial Times. Arquivado dende o orixinal o 18 de novembro de 2020. Consultado o 21 de novembro de 2020.
Kwon D (25 de novembro de 2020). "The Promise of mRNA Vaccines". The Scientist. Arquivado dende o orixinal o 22 de xaneiro de 2021. Consultado o 27 de novembro de 2020.
Carmichael F, Goodman J (2 de decembro de 2020). "Vaccine rumours debunked: Microchips, 'altered DNA' and more" (Reality Check). BBC. Arquivado dende o orixinal o 13 de marzo de 2021. Consultado o 10 de decembro de 2020.
"New crop of COVID-19 mRNA vaccines could be easier to store, cheaper to use". www.science.org (en inglés). Arquivado dende o orixinal o 5 de abril de 2022. Consultado o 6 de abril de 2022.
Lowe D (1 de marzo de 2021). "A Malaria Vaccine Candidate". Science Translational Medicine. Arquivado dende o orixinal o 6 de maio de 2021. Consultado o 7 de maio de 2021.
Knapton, Sarah (20 de setembro de 2021). "First 'variant-proof' Covid vaccine starts trials in Manchester - Retired couple Andrew Clarke, 63, and his wife Helen, 64, from Bolton, became the first to receive the mRNA vaccine on Monday". The Daily Telegraph. Arquivado dende o orixinal o 20 de setembro de 2021. Consultado o 21 de setembro de 2021.
"Gritstone Announces Dosing of First Volunteer in Trial Evaluating Self-Amplifying mRNA as a COVID-19 Vaccine Booster and Immunogenicity Enhancer". PipelineReview. 20 de setembro de 2021. Arquivado dende o orixinal o 22 de setembro de 2021. Consultado o 21 de setembro de 2021.

wikipedia.org

de.wikipedia.org

Malone RW, Felgner PL, Verma IM (agosto de 1989). "Cationic liposome-mediated RNA transfection". Proceedings of the National Academy of Sciences of the United States of America 86 (16): 6077–81. Bibcode:1989PNAS...86.6077M. PMC 297778. PMID 2762315. doi:10.1073/pnas.86.16.6077 //www.ncbi.nlm.nih.gov/pmc/articles/PMC297778 |PMC= sen título (Axuda).
Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL (marzo de 1990). "Direct gene transfer into mouse muscle in vivo". Science 247 (4949 Pt 1): 1465–8. Bibcode:1990Sci...247.1465W. PMID 1690918. doi:10.1126/science.1690918.

wipo.int

patentscope.wipo.int

Patent: WO1990011092 Arquivado 14 de outubro de 2021 en Wayback Machine.; Inventors: Philip L. Felgner, Jon Asher Wolff, Gary H. Rhodes, Robert Wallace Malone, Dennis A. Carson; Assignees: Vical Inc., Wisconsin Alumni Research Foundation; Title: "Expression of Exogenous Polynucleotide Sequences in a Vertebrate Arquivado 9 de decembro de 2021 en Wayback Machine."; (Cita: "O presente invento relaciónase coa introdución de secuencias de ADN e ARN espidas nun vertebrado para conseguir a expresión controlada dun polipéptido. É útil en terapia xénica, vacinación e en calquera situación terapéutica na cal un polipéptido debería administrarse a células in vivo"; Exemplo 8: vacinación de ARNm de ratos para producir a proteína gpl20 do VIH); Data de prioridade: 21 de marzo de 1989; data de publicación: 4 de outubro de 1990.

worldcat.org

Pardi N, Hogan MJ, Porter FW, Weissman D (abril de 2018). "mRNA vaccines — a new era in vaccinology". Nature Reviews Drug Discovery 17 (4): 261–279. ISSN 1474-1784. PMC 5906799. PMID 29326426. doi:10.1038/nrd.2017.243.
Crommelin DJ, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E (marzo de 2021). "Addressing the Cold Reality of mRNA Vaccine Stability". Journal of Pharmaceutical Sciences 110 (3): 997–1001. ISSN 0022-3549. PMC 7834447. PMID 33321139. doi:10.1016/j.xphs.2020.12.006.
Sahin U, Karikó K, Türeci Ö (outubro de 2014). "mRNA-based therapeutics — developing a new class of drugs". Nature Reviews Drug Discovery 13 (10): 759–80. ISSN 1474-1784. PMID 25233993. doi:10.1038/nrd4278.
Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. (febreiro de 2002). "Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors". The Journal of Clinical Investigation 109 (3): 409–17. ISSN 0021-9738. PMC 150859. PMID 11828001. doi:10.1172/JCI14364.
Dolgin E (setembro de 2021). "The tangled history of mRNA vaccines". Nature 597 (7876): 318–24. Bibcode:2021Natur.597..318D. ISSN 0028-0836. PMID 34522017. doi:10.1038/d41586-021-02483-w.
Hou X, Zaks T, Langer R, Dong Y (agosto de 2021). "Lipid nanoparticles for mRNA delivery". Nature Reviews Materials 6 (12): 1078–94. Bibcode:2021NatRM...6.1078H. ISSN 2058-8437. PMC 8353930. PMID 34394960. doi:10.1038/s41578-021-00358-0 //www.ncbi.nlm.nih.gov/pmc/articles/PMC8353930 |PMC= sen título (Axuda).
Wherry EJ, Jaffee EM, Warren N, D'Souza G, Ribas A (abril de 2021). "How Did We Get a COVID-19 Vaccine in Less Than 1 Year?". Clinical Cancer Research 27 (8): 2136–38. ISSN 1078-0432. PMC 8052930. PMID 33542081. doi:10.1158/1078-0432.CCR-21-0079.
Jackson NA, Kester KE, Casimiro D, Gurunathan S, DeRosa F (febreiro de 2020). "The promise of mRNA vaccines: a biotech and industrial perspective". npj Vaccines 5 (1): 11. ISSN 2059-0105. PMC 7000814. PMID 32047656. doi:10.1038/s41541-020-0159-8.

wsj.com

Hopkins JS, Eastwood J, Moriarty D (3 de marzo de 2021). "mRNA Covid-19 Vaccines Are Fast to Make, but Hard to Scale". The Wall Street Journal. Arquivado dende o orixinal o 4 de abril de 2021. Consultado o 3 de abril de 2021.